Abu Dhabi Department of Health, AbbVie, M42 Personalized Medicine Partners

The Abu Dhabi Department of Health (DoH), the regulator for the healthcare industry in the emirate, has partnered with AbbVie and M42, for a collaboration on customized personalized medicine and genomics in Abu Dhabi. M42 is a technology-enabled integrated healthcare company comprised of G42 Healthcare and Mubadala Health.

The three parties aim to advance the application of precision medicine in the diagnosis and treatment of multiple myeloma and non-small cell lung cancer. The DoH aims to drive research that contributes to policy changes and implementation of guidelines that will bring innovative approaches in healthcare to a wider range of patients.

As part of its preventive healthcare efforts, Abu Dhabi is launching the region’s first personalized precision medicine program for oncology in 2022. The program integrates predictive, personalized and precision medicine, using genomics to transform diagnosis, drug treatment and prevention, and tailor individuals to specific needs.


Hassan Sabbah, General Manager of AbbVie Gulf & Levant, said: “This collaboration aims to drive advances in precision medicine in diagnosis and treatment to help a wider range of patients in the UAE gain access to innovative treatments. initiatives and develop innovative solutions to effectively address local and regional health needs, challenges and burdens.”


Francesco Redivo, Senior Director, G42 Healthcare, an M42 company, said: “I am proud to witness how our vision of personalized healthcare is moving forward. Advancing precision medicine by maximizing the potential of the Emirati Genome Program, developing innovative solutions around access to care, and translating scientific advances into tangible patient benefits.”